SpyGlass reports 4-year BIM-IOL data: 37% IOP cut, 86% off drops, no product-related AEs

SpyGlass Pharma, Inc.

Interim 4-year data in 21 evaluable patients: mean IOP fell 37% to 15.9 mmHg from 25.1 mmHg post-washout across 75/150/300 mcg dose groups.
86% (18 of 21) remained off all topical IOP-lowering drops; 90% maintained ≥20/25 best corrected distance visual acuity.
No product-related adverse events reported; FIH trial enrolled 23 patients, with 21 evaluable at 48 months (one moved abroad, one discontinued after cancer diagnosis).
BIM-IOL System is designed to deliver bimatoprost for up to 7 years in the FIH trial; Phase 3 version targets 3 years, with a 505(b)(2) NDA planned.
CEO Patrick Mooney cites approximately 1 million U.S. cataract procedures annually in glaucoma patients as the unmet need being targeted.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.